IP Library Granted Patent US 7,022,097
Granted Patent B2
US 7,022,097 · App. 10/435,579 · Granted Apr 4, 2006

Method for treating glandular diseases and malignancies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,022,097
App. No.
10/435,579
Granted
Apr 4, 2006
Kind
B2
Abstract

A method for the in situ treatment of diseases and malignancies in a living host body. The method includes exposing a diseased or malignant gland of a host body to an effective amount of a therapeutic agent by infusing the therapeutic agent into blood flowing from the diseased or malignant gland that has been captured and contained in an isolated section associated with the gland. The contaminated blood from this isolated section is then evacuated from the host body, cleaned, detoxified and returned to the host body without exposing other glands, organs or tissue of the host body to the contaminated blood and without interrupting the normal flow of blood circulating through the host body.

Claims (26)

1. A method for treating in situ diseases and malignancies in a gland of a living host body comprising:

(a) exposing a diseased or malignant gland of a host body to an effective amount of a therapeutic agent by infusing said agent into the blood entering said gland;

(b) creating an isolated section in a major vein that spans the area where tributory veins connect with said major vein, said major vein and said tributory veins being directly associated with said gland;

(c) passing contaminated effluent blood from the tributory veins of said gland to said isolated section and capturing said contaminated blood therein;

(d) positioning a shunt in said major vein that by-passes said isolated section enabling blood to flow concurrently and continuously through said major vein; and,

(e) evacuating said contaminated, captured blood from said isolated section without exposing other glands, organs or tissue of said host body to said contaminated effluent blood and without interrupting the general blood circulation in the system of said host body.

2. The method of claim 1 wherein said isolated section is formed by inserting a catherer into said major vein, said catherer having spaced apart expandable means capable of creating said isolated section.

3. The method of claim 2 wherein one of said spaced apart expandable means prevents said contaminated effluent blood from circulating to the heart of said host body.

4. The method of claim 1 wherein said gland is a member selected from the group consisting of the adrenals, the prostate, the thyroid and the parathyroids.

5. The method of claim 1 wherein said evacuated, contaminated blood is cleaned, detoxified and returned to the general blood circulation system of the host body.

6. A method for treating in situ diseases and malignancies in a gland of a living host body comprising:

(a) exposing a diseased or malignant gland of a host body to an effective amount of a therapeutic agent by infusing said agent into the blood entering said gland, said gland being a member selected from the group consisting of the adrenals, the prostate, the thyroid and the parathyroids;

(b) creating an isolated section in a major vein that spans the area where tributory veins connect with said major vein, said major vein and said tributory veins being directly associated with said gland and said isolated section being formed by inserting a catherer into said major vein, said catheter having spaced apart expandable means capable of creating said isolated section;

(c) passing contaminated effluent blood from the tributory veins of said gland to said isolated section and capturing said contaminated blood therein;

(d) positioning a shunt in said major vein that by-passes said isolated section enabling blood to flow concurrently and continuously through said major vein, and,

(e) evacuating said contaminated, captured blood from said isolated section without exposing other glands, organs or tissue of said host body to said contaminated effluent blood and without interrupting the general blood circulation in the system of said host body.

7. The method of claim 6 wherein one of said spaced apart expandable means prevents said contaminated effluent blood from circulating to the heart of said host body.

8. The method of claim 6 wherein said evacuated, contaminated blood is cleaned, detoxified and returned to the general blood circulation system of the host body.

9. A method for treating in situ diseases and malignancies in the adrenals, the prostate, the thyroid and the parathyroid of a living host body comprising:

(a) exposing one of a diseased or malignant adrenals, prostate, thyroid and parathyroid of a host body to an effective amount of a therapeutic agent by infusing said agent into the blood entering one of said adrenals, prostate, thyroid and parathyroid;

(b) creating an isolated section in a major vein that spans the area where tributory veins connect with said major vein, said major vein and said tributary veins being directly associated with one of said adrenals, prostate, thyroid and parathyroid and said isolated section being formed by inserting a catherer into said major vein, said catherer having spaced apart expandable means capable of creating said isolated section;

(c) passing contaminated effluent blood from the tributory veins of one of said adrenals, prostate, thyroid and parathyroid to said isolated section and capturing said contaminated blood therein;

(d) positioning a shunt in said major vein that by-passes said isolated section enabling blood to flow concurrently and continuously through said major vein; and,

(e) evacuating said contaminated, captured blood from said isolated section without exposing other glands, organs or tissue of said host body to said contaminated effluent blood and without interrupting the general blood circulation in the system of said host body.

10. The method of claim 9 wherein one of said spaced apart expandable means prevents said contaminated effluent blood from circulating to the heart of said host body.

11. The method of claim 9 wherein said evacuated, contaminated blood is cleaned, detoxified and returned to the general blood circulation system of the host body.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: DELCATH SYSTEMS, INC.
Reel/Frame 068891/0510 →
SECURITY INTEREST Recorded Sep 20, 2021
From: DELCATH SYSTEMS, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
Reel/Frame 057523/0520 →
SECURITY AGREEMENT Recorded Jul 18, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B .V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049802/0378 →
SECURITY AGREEMENT Recorded May 24, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B .V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049286/0377 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ATTACHED DOCUMENT PREVIOUSLY RECORDED AT REEL: 049218 FRAME: 0441. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 23, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B .V.
To: ROSALIND MASTER FUND LP
Reel/Frame 049283/0694 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY NAME PREVIOUSLY RECORDED AT REEL: 049128 FRAME: 0792. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded May 20, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B.V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049221/0633 →
SECURITY AGREEMENT Recorded May 20, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B.V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049221/0748 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY PREVIOUSLY RECORDED AT REEL: 049127 FRAME: 0954. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENTS. Recorded May 17, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B.V.
To: ROSALIND MASTER FUND LP
Reel/Frame 049218/0441 →
SECURITY AGREEMENT Recorded May 9, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH HOLDINGS B.V.
To: ROSALIND MASTER FUND LP
Reel/Frame 049127/0954 →
SECURITY AGREEMENT Recorded May 9, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH HOLDINGS B.V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049128/0792 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2018
From: HUDSON BAY MASTER FUND LTD.
To: DELCATH SYSTEMS, INC.
Reel/Frame 045624/0355 →
SECURITY INTEREST Recorded Jun 14, 2016
From: DELCATH SYSTEMS, INC.
To: HUDSON BAY MASTER FUND LTD.
Reel/Frame 038911/0814 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 9, 2016
From: SILICON VALLEY BANK
To: DELCATH SYSTEMS, INC.
Reel/Frame 038943/0147 →
SECURITY AGREEMENT Recorded May 6, 2013
From: DELCATH SYSTEMS, INC.
To: SILICON VALLEY BANK
Reel/Frame 030359/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2003
From: GLICKMAN, MORTON DR.
To: DELCATH SYSTEMS, INC.
Reel/Frame 014065/0807 →
Continuity (1)
Related Publication 20040225251A1 · Nov 11, 2004